Immune-profiling and cell depletion experiments revealed that melanoma cell-derived Activin-A reduces the dependence on suppressive CD4+ T cells to escape immune surveillance, correlating with the diminished secretion of specific chemokines such as CXCL9 and CXCL10. This evidence concerns the gene CXCL9 and melanoma.